Evidence map›Paper›PMID 40037128›Full record

ArticleVaccine2025

Sabin inactivated polio vaccine upstream process development using fixed-bed bioreactor technology.

Ahd Hamidi, Marieke Willemsen, Thomas Robert, Jean-Christophe Drugmand, Mónika Z Ballmann, Pim Velthof, Hans Verdurmen, Ana Catarina Pinto, Jochem Pronk, Laura Palladino and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Ahd HamidiBatavia Biosciences B.V., Bioscience Park Leiden, Zernikedreef 16, 2333CL, Leiden, the Netherlands.
Marieke WillemsenBatavia Biosciences B.V., Bioscience Park Leiden, Zernikedreef 16, 2333CL, Leiden, the Netherlands.
Thomas RobertUnivercells Technologies SA, Chemin De la Vieille Cour 56a, 1400 Nivellles, Belgium.
Jean-Christophe DrugmandUnivercells Technologies SA, Chemin De la Vieille Cour 56a, 1400 Nivellles, Belgium.
Mónika Z BallmannBatavia Biosciences B.V., Bioscience Park Leiden, Zernikedreef 16, 2333CL, Leiden, the Netherlands.
Pim VelthofBatavia Biosciences B.V., Bioscience Park Leiden, Zernikedreef 16, 2333CL, Leiden, the Netherlands.
Hans VerdurmenBatavia Biosciences B.V., Bioscience Park Leiden, Zernikedreef 16, 2333CL, Leiden, the Netherlands.
Ana Catarina PintoBatavia Biosciences B.V., Bioscience Park Leiden, Zernikedreef 16, 2333CL, Leiden, the Netherlands.
Jochem PronkBatavia Biosciences B.V., Bioscience Park Leiden, Zernikedreef 16, 2333CL, Leiden, the Netherlands.
Laura PalladinoBatavia Biosciences B.V., Bioscience Park Leiden, Zernikedreef 16, 2333CL, Leiden, the Netherlands.
Menzo HavengaBatavia Biosciences B.V., Bioscience Park Leiden, Zernikedreef 16, 2333CL, Leiden, the Netherlands.
Chris YallopBatavia Biosciences B.V., Bioscience Park Leiden, Zernikedreef 16, 2333CL, Leiden, the Netherlands.
Wilfried A M BakkerBatavia Biosciences B.V., Bioscience Park Leiden, Zernikedreef 16, 2333CL, Leiden, the Netherlands. Electronic address: w.bakker@bataviabiosciences.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Eradication of polio disease remains a challenge for countries with limited health-care infrastructure. Regional vaccine production is expected to secure a sustainable and equitable availability of vaccines supporting the polio eradication end-game. Regional manufacturing of Inactivated Polio Vaccines based on the attenuated Sabin strains and using an isolator-based contained micro-facility is expected to avoid any potential risk of shortage of polio vaccines in the future, ensure equitable access to sufficient doses of IPV while securing a safe manufacturing environment. However, polio vaccine production requires biosafety level 3 containment and is complicated by the restrictions imposed from the adherent nature of the virus-producing Vero cell line. To overcome these issues that have hampered regional polio vaccine production so far, at Batavia Biosciences we developed an inactivated polio vaccine production process based on the polio Sabin strains in a contained microfacility. By incorporating a tangential flow filter coupled to a fixed-bed bioreactor with a large attachment surface area (150 m

Indexed as

BioreactorsPoliomyelitisPoliovirusPoliovirus Vaccine, InactivatedAnimalsChlorocebus aethiopsHumansVero CellsPoliovirus Vaccine, InactivatedEquipment developmentFixed-bed bioreactorInactivated polio vaccineLow cost of goodsSabin attenuated poliovirussIPVTangential flow filtrationVaccines

Identifiers

PMID40037128
PMCPMC12042818

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.